



Vivimed

Investor Release

**Vivimed's FDF facility which obtained UKRAINE PICS approval in October 2017, obtains new product registrations and now signs Distribution Agreement**

**Hyderabad, India, February 12, 2018** – Vivimed Labs Limited (“Vivimed” or the Company), a niche Pharmaceuticals and Specialty Chemicals’ company, announced today its unit 1 FDF manufacturing facility located in Hyderabad, post certification by Ukraine FDA, has successfully registered 8 products in anti viral, pain management and cough suppressants segment.

Vivimed has now inked a distribution agreement with ‘Alter Ego LLC’, Kieve, Ukraine which has more than a decade of presence in Ukraine, Russia and CIS regions. Vivimed is expecting revenues upwards of 10 million USD for FY19 from CIS region.

Commenting on the development, **Mr. Sandeep Varalwar, Executive Director** said:

“This agreement between Vivimed and Alter Ego is in line with company’s vision of growth in CIS markets. The relationship will go a long way in establishing a robust growth in CIS markets and Vivimed will continue to add more new products to its range leveraging its strength in API manufacturing for new molecules.

**About Vivimed Labs:**

Vivimed is a Pharmaceuticals and Specialty Chemicals company head quartered in Hyderabad, India. It has manufacturing footprint across India, Europe and South America across its line of business and employs close to 2000 personnel across the world. Vivimed reported sales of about INR 15 bn for the financial year ended March 31, 2017.

For further information on Vivimed, visit [www.vivimedlabs.com](http://www.vivimedlabs.com)

\*\*\* \*\*

For VIVIMED LABS LTD.

A handwritten signature in blue ink, appearing to read 'Sandeep Varalwar', written over the printed name 'Company Secretary'.

